Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6.

2.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

3.

Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.

Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA.

Mod Pathol. 2009 Jul;22(7):866-71. doi: 10.1038/modpathol.2009.57. Epub 2009 Apr 24.

4.

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29.

5.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.

6.

TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Gopalan A, Leversha MA, Dudas ME, Maschino AC, Chang J, Al-Ahmadie HA, Chen YB, Tickoo SK, Reuter VE, Fine SW.

Histopathology. 2013 Aug;63(2):279-86. doi: 10.1111/his.12153. Epub 2013 May 23.

7.

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2011 Apr;71(5):489-97. doi: 10.1002/pros.21265. Epub 2010 Sep 28.

PMID:
20878952
8.

CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.

de Muga S, Hernández S, Salido M, Lorenzo M, Agell L, Juanpere N, Lorente JA, Serrano S, Lloreta J.

Cancer Biomark. 2012-2013;12(1):21-30. doi: 10.3233/CBM-2012-00288.

PMID:
23321466
9.

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ.

Am J Surg Pathol. 2011 Jul;35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761.

10.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

11.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

12.

TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.

Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ.

Mod Pathol. 2009 Nov;22(11):1415-22. doi: 10.1038/modpathol.2009.121. Epub 2009 Sep 4.

13.

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8.

14.

TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.

Cancer Biol Ther. 2009 Jan;8(2):125-30. Epub 2009 Feb 4.

PMID:
19029822
15.

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG.

J Clin Pathol. 2007 Nov;60(11):1238-43. Epub 2007 Jan 26.

16.

Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L.

Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005. Epub 2013 Jul 12.

PMID:
23850495
17.

[TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].

Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.

Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6. Chinese.

PMID:
21914348
18.

TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.

Dong J, Xiao L, Sheng L, Xu J, Sun ZQ.

Asian Pac J Cancer Prev. 2014;15(7):3099-103.

19.

Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.

Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.

Prostate. 2014 Dec;74(16):1647-54. doi: 10.1002/pros.22882. Epub 2014 Sep 22.

PMID:
25252136
20.

The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA.

Hum Pathol. 2012 May;43(5):644-9. doi: 10.1016/j.humpath.2011.06.018. Epub 2011 Sep 19.

Supplemental Content

Support Center